Fisher Asset Management LLC Raises Position in Pfizer Inc. $PFE

Key Points

• Fisher Asset Management increased its Pfizer stake by 5.4% in the fourth quarter, adding more than 2.6 million shares and bringing its holdings to about 51.95 million shares valued at roughly $1.29 billion.
• Pfizer’s latest quarterly results topped expectations, with EPS of $0.75 versus an estimated $0.72 and revenue of $14.45 billion, up 5.4% year over year.
• The company also declared a quarterly dividend of $0.43 per share, implying an annualized yield of 6.6%, while analysts currently rate the stock a consensus Hold with an average price target of $28.61.

Fisher Asset Management LLC raised its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 5.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 51,952,106 shares of the biopharmaceutical company's stock after acquiring an additional 2,664,052 shares during the quarter. Fisher Asset Management LLC owned approximately 0.91% of Pfizer worth $1,293,607,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also modified their holdings of PFE. Franklin Resources Inc. boosted its stake in shares of Pfizer by 47.8% during the 3rd quarter. Franklin Resources Inc. now owns 25,070,148 shares of the biopharmaceutical company's stock worth $638,787,000 after acquiring an additional 8,108,887 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Pfizer by 1.3% during the 4th quarter. Vanguard Group Inc. now owns 541,346,182 shares of the biopharmaceutical company's stock worth $13,479,520,000 after acquiring an additional 7,031,162 shares during the last quarter. Neuberger Berman Group LLC raised its position in shares of Pfizer by 203.8% during the 3rd quarter. Neuberger Berman Group LLC now owns 9,012,811 shares of the biopharmaceutical company's stock valued at $229,346,000 after purchasing an additional 6,045,763 shares during the period. Ameriprise Financial Inc. raised its position in shares of Pfizer by 48.2% during the 3rd quarter. Ameriprise Financial Inc. now owns 18,373,140 shares of the biopharmaceutical company's stock valued at $468,174,000 after purchasing an additional 5,978,927 shares during the period. Finally, AQR Capital Management LLC raised its position in shares of Pfizer by 120.9% during the 3rd quarter. AQR Capital Management LLC now owns 9,505,615 shares of the biopharmaceutical company's stock valued at $230,986,000 after purchasing an additional 5,202,884 shares during the period. Hedge funds and other institutional investors own 68.36% of the company's stock.

Pfizer Stock Performance

Shares of NYSE PFE opened at $25.92 on Monday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.94 and a current ratio of 1.25. The company has a market cap of $147.72 billion, a P/E ratio of 19.79 and a beta of 0.35. The firm's fifty day moving average is $26.86 and its two-hundred day moving average is $26.24. Pfizer Inc. has a 52-week low of $22.88 and a 52-week high of $28.75.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.72 by $0.03. The company had revenue of $14.45 billion for the quarter, compared to the consensus estimate of $13.84 billion. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. Pfizer's revenue for the quarter was up 5.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.92 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, analysts anticipate that Pfizer Inc. will post 2.99 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 12th. Shareholders of record on Friday, May 8th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 6.6%. The ex-dividend date is Friday, May 8th. Pfizer's payout ratio is currently 131.30%.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on PFE shares. CICC Research started coverage on shares of Pfizer in a research report on Thursday, April 16th. They set an "outperform" rating and a $33.00 price objective on the stock. Wolfe Research restated an "underperform" rating and set a $26.00 price objective on shares of Pfizer in a research report on Thursday, May 14th. Weiss Ratings upgraded shares of Pfizer from a "hold (c-)" rating to a "hold (c)" rating in a research report on Wednesday, May 6th. UBS Group raised their price objective on shares of Pfizer from $25.00 to $27.00 and gave the company a "neutral" rating in a research report on Monday, April 13th. Finally, Cantor Fitzgerald restated a "neutral" rating and set a $27.00 price objective on shares of Pfizer in a research report on Wednesday, February 4th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, twelve have given a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Hold" and an average price target of $28.61.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer’s Phase 3 Lyme vaccine trial is nearing completion, which could be an important step toward a new potential growth driver if the data are supportive. Pfizer’s Phase 3 Lyme Vaccine Trial Nears the Finish Line: What Investors Should Know
• Positive Sentiment: Pfizer is also advancing a broader pneumococcal vaccine strategy, including positive Phase 2 infant data and a new Phase 3 pediatric program, which supports the company’s long-term vaccine franchise. Pfizer’s Broader Pneumococcal Vaccine Push Might Change The Case For Investing In Pfizer (PFE)
• Positive Sentiment: Pfizer’s HYMPAVZI expansion in Europe and the new Rigel licensing arrangement for VEPPANU add to the company’s revenue opportunities beyond its legacy products. Here’s Why Pfizer (PFE) Is One of the Most Undervalued US Stocks Pfizer’s VEPPANU License With Rigel Adds New Angle To PFE Story
• Neutral Sentiment: Pfizer is testing new tablet formulations for tafamidis and migraine treatments in early-stage bioequivalence studies, which are routine development updates but do not yet imply a major commercial impact. Pfizer Tests New Tafamidis Tablet Forms in Phase 1 Bioequivalence Study Pfizer Advances New Migraine Tablet Formulation With Phase 1 Bioequivalence Study
• Neutral Sentiment: Pfizer also disclosed an observational biosimilar study in Japan, another incremental pipeline item that appears more informational than immediately market-moving. Pfizer’s Bevacizumab Biosimilar Study in Japan: What Investors Should Watch
• Negative Sentiment: Pfizer ended an early Phase 1 KRAS cancer trial, which may be viewed as a setback in one of the company’s closely watched oncology programs. Pfizer Terminates Early KRAS Cancer Trial: What It Means for PFE Investors
• Negative Sentiment: Some analyst coverage continues to flag patent risk and competitive pressure, which may limit enthusiasm despite the recent pipeline progress. J&J & Pfizer Face Patent Risks: Which Stock Looks Better Positioned?

Pfizer Profile

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.